SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precision Autophagy Inhibition

Executive Summary: SAR405 is a highly potent and selective ATP-competitive inhibitor of Vps34, the class III phosphoinositide 3-kinase (PI3K), with a Kd of 1.5 nM and IC₅₀ of 1 nM against recombinant human Vps34 (APExBIO, SAR405). This inhibitor demonstrates remarkable selectivity, sparing class I/II PI3Ks and mTOR at concentrations up to 10 μM. SAR405 blocks autophagosome formation and impairs late endosome-lysosome function, resulting in defective cathepsin D maturation and accumulation of swollen vesicles (Park et al., 2023). Its mechanism provides a precision tool to dissect autophagy and vesicle trafficking in both cancer and neurodegenerative disease models. Recent insights into AMPK-ULK1-Vps34 signaling further underscore the value of SAR405 for pathway-specific studies [1].

Biological Rationale

Vps34 is the only class III PI3K in mammals and is crucial for autophagy initiation, vesicle trafficking, and endolysosomal homeostasis. Autophagy is a conserved catabolic process where cytoplasmic components are sequestered into autophagosomes and delivered to lysosomes for degradation. Dysregulation of autophagy is implicated in cancer, neurodegeneration, and metabolic disorders (Park et al., 2023). The Vps34-Atg14-ULK1 axis is a nodal point for autophagosome biogenesis and integrates upstream nutrient and energy signals. Inhibition of Vps34 provides a unique means to dissect these regulatory networks, especially in the context of AMPK and mTOR signaling. APExBIO supplies SAR405 to enable pathway-specific modulation without confounding effects on other PI3K isoforms [Product].

Mechanism of Action of SAR405

SAR405 is an ATP-competitive inhibitor that binds within the ATP-binding cleft of Vps34, blocking its kinase activity at nanomolar concentrations. This inhibition is highly selective: SAR405 does not inhibit class I or II PI3Ks or mTOR at concentrations up to 10 μM, as shown using recombinant enzymes and cell-based assays [Product]. By preventing Vps34-mediated phosphorylation of phosphatidylinositol, SAR405 disrupts the initiation of autophagy and impairs vesicle trafficking. Cellular phenotypes include accumulation of swollen late endosome-lysosomes, defective cathepsin D maturation, and blocked autophagosome formation in GFP-LC3 HeLa and H1299 cells. Synergistic effects are observed when SAR405 is combined with mTOR inhibitors such as everolimus, resulting in enhanced autophagy inhibition [1]. SAR405 is soluble in DMSO (>10 mM), insoluble in water, and soluble in ethanol with ultrasonic assistance. Stock solutions should be stored below -20°C.

Evidence & Benchmarks

• SAR405 displays a dissociation constant (Kd) of 1.5 nM and IC₅₀ of 1 nM against recombinant human Vps34 at 25°C in kinase buffer (APExBIO, Product page).
• Does not significantly inhibit class I/II PI3Ks or mTOR at concentrations up to 10 μM (APExBIO, Product page).
• Prevents autophagosome formation in GFP-LC3 HeLa and H1299 cell models within 1–4 hours of exposure, as measured by LC3 puncta and electron microscopy (Park et al., 2023).
• Impedes cathepsin D maturation and causes vesicular swelling in late endosome-lysosome compartments (Park et al., 2023).
• Synergizes with mTOR inhibitors (e.g., everolimus) to enhance autophagy inhibition in vitro ([3]).
• Recent studies show AMPK, previously thought to promote autophagy, actually inhibits ULK1-dependent autophagy induction and suppresses Vps34-Atg14 complex signaling during severe energy stress (Park et al., 2023).

This article extends prior reviews like SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precision Autophagy Studies by integrating the latest AMPK-ULK1-Vps34 signaling paradigm, and clarifies SAR405’s use in pathway-specific autophagy inhibition beyond generic PI3K blockade. For a broader translational perspective, see SAR405 and the Future of Autophagy Research, which outlines strategic guidance for applying SAR405 in disease models; this article updates the mechanistic context based on recent AMPK findings.

Common Pitfalls or Misconceptions

• SAR405 is not a pan-PI3K inhibitor: It does not inhibit class I/II PI3Ks or mTOR at relevant concentrations; its effects are specific to Vps34.
• Inhibition of autophagy is context-dependent: Complete suppression of autophagy by SAR405 may not occur under all metabolic or stress conditions, especially where alternative pathways are engaged (Park et al., 2023).
• SAR405 does not induce cell death directly: Its primary effect is on vesicle trafficking and autophagy blockade; cytotoxicity is context- and model-dependent.
• Solubility is limited in aqueous buffers: SAR405 is insoluble in water and should be prepared in DMSO or ethanol with ultrasonic assistance (Product page).
• Long-term storage of solutions is not recommended: Prepare fresh working dilutions to ensure potency (Product page).

Applications, Limits & Misconceptions

SAR405 is widely used to dissect autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment in cell and animal models. It is valuable in cancer research for evaluating the role of autophagy in tumor progression and therapy resistance. In neurodegenerative disease models, SAR405 helps clarify the contribution of vesicle trafficking defects to pathology. However, its use is limited to research applications; it is not approved for clinical or in vivo therapeutic use. The compound’s specificity for Vps34 makes it an unsuitable tool for studies seeking to address pan-PI3K or mTOR signaling. Additionally, SAR405’s effects may be masked or altered by compensatory energy stress responses (e.g., AMPK activation), as recent mechanistic data suggest that energy crisis can suppress autophagy independently of Vps34 inhibition (Park et al., 2023).

Workflow Integration & Parameters

For optimal results, SAR405 should be dissolved in DMSO to a final stock concentration above 10 mM and stored at –20°C. Working solutions should be prepared fresh before each experiment. In cell culture, effective concentrations typically range from 10 nM to 1 μM, with effects observable within 1–4 hours. For imaging autophagy, GFP-LC3 puncta formation is a validated readout. When studying synergistic inhibition, co-treatment with mTOR inhibitors (e.g., everolimus) is recommended. Avoid long-term storage of working solutions and exposure to aqueous buffers to preserve potency [Product].

Conclusion & Outlook

SAR405, provided by APExBIO, represents a highly selective and potent research tool for dissecting Vps34 kinase signaling, autophagy inhibition, and vesicle trafficking modulation. Its nanomolar specificity allows for pathway-precise interrogation of autophagosome formation, lysosome impairment, and disease-related mechanisms in cancer and neurodegeneration. Recent advances in understanding the AMPK-ULK1-Vps34 axis further enhance the interpretability and translational value of experiments using SAR405. For further troubleshooting or advanced workflows, see SAR405: Selective ATP-Competitive Vps34 Inhibitor for Next-Gen Research, which offers detailed protocols and expert guidance. SAR405 will continue to drive innovation in autophagy and vesicle biology research.